Home | CANbridge

News Release

CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan

2024/12/18

CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients

2024/12/18

CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies

2024/11/15

CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration

2024/11/13

CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate

2024/10/28

CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA

2024/09/30

CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024

2024/08/19

CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics

2024/08/07

CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease

2024/07/08

CANbridge Announces Expansion of LIVMARLI^® Label to Include Patients as Young as 3 Months in China

2024/05/21

More News

Investors

Partners

Contact:bd@canbridgepharma.com

Detail

Our Pipeline

We are building a pipeline of compelling investigational therapies targeting indications for which we believe gene therapy can have the greatest impact in patients with rare genetic diseases.

Rare Disease

Gene Therapy

Our Products

Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT).

Livmarli is an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT).

NERLYNX® (Neratinlib) is a potent irreversible tyrosine kinase inhibitor, that inhibits tumor growth and metastasis through blocking pan-HER family proteins (HER1, HER2, and HER4) and downstream signal transduction.

Click for more

Investor Relations